CHRW
C.H. Robinson Worldwide, Inc.
CHRW has the edge over RKLB overall, supported by lower modeled downside and stronger modeled upside.
RKLB
Rocket Lab USA, Inc.
RKLB offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
CHRW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Under pressure | |
| Stable |
CHRW's revenue and profitability are currently healthy, and its balance sheet is stable, but its cash flow is under pressure.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
CHRW PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $85.25 | -37% |
| Forward | 18x | $134 | — |
| Fair | 24x | $132 | -1.6% |
| Current | 24x | $134 | — |
| Expensive | 34x | $188 | +40% |
Historical ranges are pointers, not guarantees.
CHRW's PE is in its fair range at 24x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
CHRW Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for CHRW, with profitability holding steady.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
RKLB has the edge over CHRW on the outlook, with more favorable profitability expectations.
CHRW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.30 | +31% |
| Q3 2026 | $5.57 | +13% |
| Q2 2026 | $5.24 | +19% |
| Q1 2026 | $4.94 | +18% |
| Q4 2025 | $4.83 | +25% |
| Q3 2025 | $4.94 | +70% |
| Q2 2025 | $4.40 | +58% |
| Q1 2025 | $4.19 | +65% |
| Q4 2024 | $3.86 | +42% |
CHRW has the edge over RKLB on earnings quality, reporting a profit while its opponent remains loss making.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
CHRW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.4B | +30% |
| Q2 2026 | $4.9B | +19% |
| Q1 2026 | $4B | -0.8% |
| Q4 2025 | $3.9B | -6.5% |
| Q3 2025 | $4.1B | -11% |
| Q2 2025 | $4.1B | -7.7% |
| Q1 2025 | $4B | -8.3% |
| Q4 2024 | $4.2B | -0.9% |
CHRW's revenue is recovering but still below its 2022 peak: $5.4B last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.1% | -0.3 points |
| Q2 2026 | 5.2% | 0 points |
| Q1 2026 | 4.4% | 0 points |
| Q4 2025 | 4.6% | +0.3 points |
| Q3 2025 | 5.3% | +1.5 points |
| Q2 2025 | 5.2% | +1.2 points |
| Q1 2025 | 4.4% | +1.5 points |
| Q4 2024 | 4.4% | +1.8 points |
CHRW has the edge over RKLB on profitability, with a higher operating margin.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over CHRW on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
CHRW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $120.5M | -55% |
| Q2 2026 | $30.9M | -86% |
| Q1 2026 | $66M | -36% |
| Q4 2025 | $302.4M | +14% |
| Q3 2025 | $269.5M | +161% |
| Q2 2025 | $219.8M | +38% |
| Q1 2025 | $103.2M | +$145.1M |
| Q4 2024 | $265.3M | +514% |
CHRW has the edge over RKLB on cash generation, producing positive trailing cash flow while its opponent burns cash.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
CHRW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -1M shares |
| 1 year | -2.2% | -2.6M shares |
| 3 years | -0.9% | -1M shares |
| 5 years | -11% | -14.7M shares |
| Available history | -13% | -17.9M shares |
CHRW has the edge over RKLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $207.7M |
| Q2 2026 | $219.5M |
| Q1 2026 | $212.7M |
| Q4 2025 | $114.4M |
| Q3 2025 | $111.5M |
| Q2 2025 | $81.1M |
| Q1 2025 | $47.7M |
| Q4 2024 | — |
CHRW spent $754M buying back its own shares over the past year, about three times what it spent the year before.
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has 652M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CHRW Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.6x | Healthy |
| Q1 2026 | 1.3x | Healthy |
| Q4 2025 | 1.0x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.5x | Healthy |
| Q4 2024 | 1.6x | Healthy |
CHRW's net debt is about 1.7 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CHRW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 15.4 | Oversold |
CHRW's weekly RSI is 41 (neutral) and its Stochastic is 15 (oversold).
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
CHRW PE vs Industrials Sector
| Metric | CHRW | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 0.2% above |
| PE % | 51 | 58 | 7 pts below |
CHRW is trading at 24x earnings, in line with the Industrials sector's median of 24x.
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
CHRW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $139.0 | 3.3% below |
| 20 week MA | $154.1 | 13% below |
| 50 week MA | $166.9 | 19% below |
| 100 week MA | $139.0 | 3.3% below |
| 200 week MA | $115.3 | 17% above |
CHRW has fallen below most of its moving averages, though it's still 17% above its 200-week average.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB has the edge over CHRW on trend strength, trading above more of its moving averages.
CHRW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $77.9 | $94.7 | +21% |
| 2021 | $94.7 | $102.5 | +8.2% |
| 2022 | $102.5 | $93.1 | -9.1% |
| 2023 | $93.1 | $86.4 | -7.2% |
| 2024 | $86.4 | $103.9 | +20% |
| 2025 | $103.9 | $164.6 | +58% |
| 2026 YTD | $164.6 | $134.4 | -18% |
CHRW has finished higher in four of the last six years. It's down 18% so far in 2026.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB has the edge over CHRW on returns for 2026, with the stronger performance.